RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Recommendation of “Hold” by Brokerages

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been given a consensus rating of “Hold” by the nine research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $5.29.

A number of analysts have commented on RAPT shares. JPMorgan Chase & Co. cut shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Piper Sandler cut RAPT Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $8.00 to $2.00 in a research note on Monday, November 11th. Wells Fargo & Company lowered their target price on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. HC Wainwright upgraded RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price target on the stock in a report on Thursday, December 26th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $2.00 price objective (down previously from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th.

Hedge Funds Weigh In On RAPT Therapeutics

Institutional investors have recently modified their holdings of the company. Medicxi Ventures Management Jersey Ltd acquired a new stake in RAPT Therapeutics in the 4th quarter valued at $35,316,000. TCG Crossover Management LLC bought a new position in shares of RAPT Therapeutics in the fourth quarter valued at $19,751,000. Orbimed Advisors LLC acquired a new position in shares of RAPT Therapeutics during the fourth quarter valued at about $20,754,000. Foresite Capital Management VI LLC bought a new stake in shares of RAPT Therapeutics during the fourth quarter worth about $19,750,000. Finally, RTW Investments LP bought a new stake in shares of RAPT Therapeutics during the fourth quarter worth about $18,587,000. 99.09% of the stock is owned by institutional investors and hedge funds.

RAPT Therapeutics Stock Performance

NASDAQ:RAPT opened at $1.09 on Friday. RAPT Therapeutics has a 52 week low of $0.79 and a 52 week high of $10.05. The firm’s fifty day moving average is $1.30 and its 200-day moving average is $1.61. The firm has a market cap of $38.10 million, a P/E ratio of -0.39 and a beta of 0.03.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.